For Quotient, the deal expands its service portfolio and will integrate drug substance, drug product, and clinical testing capabilities under one portfolio, according to the firm. Arcinova has 160 employees and provides drug substance, drug product, and bioanalysis services to over 200 pharma and biotech customers around the world, the company said.

Arcinova's minority equity partner BGF, which has backed Arcinova since 2018, will exit the business as part of the deal.

Tackling the next hurdle in cell and gene therapy: Manufacturing
Although innovation continues to occur at lightning fast speeds in the cell and gene therapy space, commercialization and manufacturing of these technologies...

Fujifilm Diosynth to establish viral vector manufacturing in Boston
Contract development and manufacturing organization Fujifilm Diosynth Biotechnologies will establish a new process development and manufacturing facility...

Tubulis, WuXi partner to bring antibody-drug conjugates to clinical trials
Tubulis and WuXi Biologics have announced a strategic collaboration to manufacture Tubulis' next-generation antibody-drug conjugates toward investigational...

Nanoform begins first-in-human trial by year end
Nanoform Finland plans to start the first human clinical trial of its drug candidate using the company's Controlled Expansion of Supercritical Solutions...

Quotient, CytoAgents develop COVID-19 cytokine storm treatment
A new collaboration between Quotient Sciences and CytoAgents will accelerate the development of a lead COVID-19 drug candidate to human clinical trials,...